Use of liquid biopsies in clinical oncology: Pilot experience in 168 patients

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5497-5505

  Schwaederle, Maria ^a   Husain, Hatim ^a   Fanta, Paul T ^a   Piccioni, David E ^a   Kesari, Santosh ^a   Schwab, Richard B ^a   Patel, Sandip P ^a   Harismendy, Olivier ^b   Ikeda, Megumi ^a   Parker, Barbara A ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR RECEPTOR; CIRCULATING TUMOR DNA; DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ADULT; BONE METASTASIS; BRAIN CANCER; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; EGFR GENE; ERBB2 GENE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MET GENE; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR BIOPSY; BLOOD; CLINICAL TRIAL; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; LIQUID BIOPSY; MIDDLE AGED; NEOPLASM; ONCOLOGY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY;

CIRCULATING TUMOR DNA; DNA, NEOPLASM; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIQUID BIOPSY; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84995670109     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0318     Document Type: Conference Paper

References (43)

1. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 2015;14:1488-94.
2. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist 2014;19:631-6.
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
4. Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med 2014;276:41-51.
5. Ng CKY, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther 2012;12:1021-32.
6. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
7. Francis G, Stein S. Circulating cell-free tumour DNA in themanagement of cancer. Int J Mol Sci 2015;16:14122-42.
8. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987;23:707-12.
9. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
10. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-12.
11. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9.
12. Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer 2015;112:352-6.
13. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, et al. Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012;7:e47020.
14. Mouliere F, El Messaoudi S, Gongora C, Guedj A-S, Robert B, Del Rio M, et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol 2013;6:319-28.
15. Spindler KLG, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One 2015;10:e0108247.
16. Spindler K-LG, Pallisgaard N, Andersen RF, Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014;135:2215-22.
17. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 2015;6:12809-21.
18. Hyman DM, Diamond EL, Vibat CRT, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov 2015;5:64-71.
19. Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, et al. Circulating tumor DNA analysis as a real-timemethod for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2014;2:42.
20. Pantel K, Diaz LA, Polyak K. Tracking tumor resistance using 'liquid biopsies'. Nat Med 2013;19:676-7.
21. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10:472-84.
22. Randall JM, Erlander MG, Vibat CRT, Hancock S, Melnikova V, Cohen EEW, et al. Non-invasive monitoring of urinary KRAS circulating tumor DNA for treatment response and minimal residual disease in patients with lung adenocarcinoma. J Clin Oncol 33, 2015(suppl; abstr e19092).
23. Husain H, Kosco K, Vibat CRT, Melnikova V, Erlander MG, Cohen EEW, et al. Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. J Clin Oncol 33, 2015(suppl; abstr 8081).
24. Lanman R, Mortimer S, Zill O, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 2015;10:e0140712.
25. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-31.
26. Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010;1:274-8.
27. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5:11-5.
28. Kondo Y, Arii S, Mori A, Furutani M, Chiba T, Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res 2000;6:622-30.
29. Nakao M, Hata J, Manabe N, Okanobu H, Tanaka S, Haruma K, et al. Evaluation of colon cancer vascularity by flash echo imaging. Scand J Gastroenterol 2008;43:223-8.
30. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
31. ctDNA is a specific and sensitive biomarker in multiple human cancers. Cancer Discov 2014;4:OF8.
32. Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 2015;61:514-22.
33. Magbanua MJM, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, et al. Genomic profiling of isolated circulating tumor cells frommetastatic breast cancer patients. Cancer Res 2013;73:30-40.
34. Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol 2014;6:43-51.
35. Talasaz AA, Mortimer S, Sebisanovic D, Siew LM, Zapanta A, Mei G, et al. Use of the GUARDANT360 noninvasive tumor sequencing assay on 300 patients across colorectal, melanoma, lung, breast, and prostate cancers and its clinical utility. J Clin Oncol 32, 2014(suppl; abstr e22041).
36. Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel inmetastatic solid tumor patients. Oncotarget 2015;6:40360-9.
37. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016;7:9707-17
38. Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014;25:1959-65.
39. Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, et al. Breast cancer experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract 2015;11:442-9.
40. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012;18:1177-85.
41. Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014;134:1207-13.
42. Schwaederle M, Vladimir L, Validire P, Hansson J, Lacroix L, Soria JC, et al. VEGF-A expression correlates with tp53 mutations in non-small cell lung cancer: implications for anti-angiogenesis therapy. Cancer Res 2015;75: 1187-90.
43. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013;4:705-14.